Autopsy report · NCT04084158

A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

“combination arm delevelped significant poor prognosis”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 100 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 2

Sponsor

Zhejiang Cancer Hospital

Sponsor type

University, hospital or other

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

Toripalimab injection (JS001); Paclitaxel, Albumin-Bound; Radiotherapy; Platinum-Based Drug

Participants

100 (planned, not actual)

Sites

1

Countries

China

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.